Acadia Q2 Revenue Jumps 16%, Raises Full-Year Outlook on Strong DAYBUE and NUPLAZID Sales
ACAD sits 38% above its 52-week low of $19.69.
Summary
Acadia Pharmaceuticals reported Q2 2026 revenue of $308 million, up 16% year-over-year, and raised its full-year revenue guidance. DAYBUE sales surged 30% to $125 million, while NUPLAZID grew 10% to $183 million. The company also lowered R&D expense guidance and highlighted a strong cash position of $956 million.
Key Events · Earnings and Guidance · ACAD
-
Q2 Revenue Beats Expectations
Total revenues reached $308 million, a 16% increase year-over-year, driven by DAYBUE ($125 million, +30%) and NUPLAZID ($183 million, +10% on an adjusted basis).
-
Full-Year Guidance Raised
Management increased 2026 total revenue guidance to $1.24–$1.30 billion (from $1.22–$1.28 billion), with DAYBUE guidance raised to $480–$510 million and NUPLAZID reaffirmed at $760–$790 million.
-
R&D Expense Guidance Lowered
R&D expense guidance was reduced to $355–$380 million (from $385–$410 million), which may improve operating margins.
-
Strong Cash Position
Cash, cash equivalents, and investments totaled $956 million at quarter-end, up from $820 million at year-end 2025, providing ample runway for pipeline development.
Analysis · ACAD · Life Sciences
A strong second quarter saw total revenue climb 16% to $308 million, fueled by a 30% surge in DAYBUE and a 10% adjusted increase in NUPLAZID. Reflecting confidence in both franchises, management raised full-year revenue guidance to $1.24–$1.30 billion and lowered R&D expense guidance, a move that could bolster profitability. With $956 million in cash and no debt, the company is well-funded to advance its pipeline. A key catalyst looms: the Phase 2 remlifanserin readout in Alzheimer's disease psychosis, expected in September–October 2026, which could significantly expand the addressable market.
At the time of this filing, ACAD was trading at $27.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $19.69 to $28.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.